Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/DexCom upgraded to 'Buy' after strong Q1/26 growth and attractive valuation.

DXCM

$72.76

+$0.03 +0.04%

DexCom upgraded to 'Buy' after strong Q1/26 growth and attractive valuation.

Analyst Insights

21 May 2026

Seeking Alpha

View Source

Bullish

DexCom's Q1/26 results showed 15% revenue growth and a 90.9% increase in operating income, prompting an upgraded rating to 'Buy'. The company raised its 2026 revenue and margin guidance, driven by international expansion, broader U.S. coverage for type 2 diabetes, and a planned $1 billion share buyback. With a price-to-free-cash-flow ratio of 20 and intrinsic value estimates up to $115, DexCom appears slightly undervalued with strong growth potential.

More News (DXCM)

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...

Market News

Bullish

2 days ago